background: Ovulation induction treatment with metformin, either alone or in combination with clomiphene citrate (CC), remains controversial even though previous randomized trials have examined this. methods: A double blinded multi-centre randomized trial was undertaken including 171 women with anovulatory or oligo-ovulatory polycystic ovary syndrome. Women with high body mass index (BMI) . 32 kg/m 2 received placebo ('standard care') or metformin;
Introduction
Polycystic ovary syndrome (PCOS) is the usual etiology of anovulatory infertility (Hull, 1987) and is associated with increased insulin resistance. Treatment with the insulin sensitising agent metformin has been proposed as an alternative to clomiphene citrate (CC), the long established effective ovulation induction treatment for women with anovulatory PCOS (Nestler et al., 1998) . Early systematic reviews of randomized controlled trials (RCTs) showed that metformin was more effective than placebo for inducing ovulation, however, these trials and systematic reviews were vastly underpowered to detect differences in clinically relevant outcomes such as pregnancy and live birth (Lord et al., 2005; Creanga et al., 2008) . The addition of metformin to CC in combination therapy was proven to be more effective than CC alone only among women with known CC resistance (Al-Inany and Johnson, 2006) .
In New Zealand our standard treatment for anovulatory infertility in women with PCOS has traditionally been lifestyle intervention (with emphasis on exercise and weight-reducing diet) for women whose BMI is greater than 32 kg/m 2 and CC ovulation induction therapy for women whose body mass index (BMI) is 32 kg/m 2 or less. We designed a randomized trial to ascertain whether the addition of metfomin to standard treatment provided any clinically relevant benefit. We also studied the relative efficacy of CC, metformin and both among women with BMI ≤ 32 kg/m 2 ; metformin versus placebo among women with BMI . 32 kg/m 2 .
Since initiating our trial, further RCTs have been published with conflicting results. The largest RCT, a high quality American multi-centre trial, showed a significant benefit of CC over metformin (live birth rate 22.5 versus 7.2%; Legro et al., 2007) . This was widely accepted as definitive evidence that CC should remain the first line treatment for anovulatory PCOS, with apparently no place for metformin first line (Al-Inany and Johnson, 2006) , results largely confirmed by the most recent RCT from Malaysia (live birth rate 15.4% for CC versus 7.9% for metformin; Zain et al., 2008) . However, a smaller Italian RCT had suggested the live birth rate for metformin (52.0%) was higher than that for CC (18.0%) for non-obese women with anovulatory PCOS (Palomba et al., 2005) . A Dutch RCT has shown no benefit of combination therapy CC plus metformin versus CC alone as a first line ovulation induction treatment for women with PCOS (Moll et al., 2006) and a British trial showed no significant benefit of metformin for obese women (Tang et al., 2006) . These RCT findings were assimilated into the Thessaloniki consensus recommendation that appeared to close the door on metformin, stating 'use of metformin should be restricted to those patients with glucose intolerance' (The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008; Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008) . Others, however, have questioned whether metformin should continue to have a more prominent role, especially where immediacy of achieving pregnancy is not paramount (Nestler, 2008; Palomba et al., 2009) . The recent updated Cochrane review (Tang et al., 2010) included these RCTs and concluded that 'the use of metformin in improvement of reproductive outcomes or in reducing the risk of developing metabolic syndrome in women with PCOS appears to be limited', but that 'some women with PCOS may benefit from using insulin sensitizers' and that 'more research is needed to improve patient selection'. Thus a level of uncertainty remains regarding the role of metformin in PCOS.
The aim of this trial was to assess whether metformin provides benefit when added to standard treatment and to assess the best first line treatment for women with ovulation dysfunction related to PCOS.
Materials and Methods

Study design
A multi-centre double-blind placebo-controlled parallel randomized trial was conducted among women with oligo-or anovulatory infertility owing to PCOS. Approval was granted by the New Zealand Multi-Region Ethics Committee and all participants gave written informed consent. The trial methodology meets CONSORT statement criteria and has previously been described in detail (Johnson, 2006) .
In brief, we included anovulatory or oligo-ovulatory women with PCOS defined by the Rotterdam consensus criteria (The Rotterdam ESHRE/ASRMSponsored PCOS Consensus Workshop Group, 2004; Rotterdam ESHRE/ ASRM-Sponsored PCOS Consensus Workshop Group, 2004) and excluded couples who had undergone previous fertility treatment involving more than 5 months treatment with CC or metformin. We also excluded couples in whom any other important infertility factor was known to be present, including known tubal factor where at least one fallopian tube was blocked (although a tubal patency test was not a prerequisite for trial entry). However, women known to have stage 1 or 2 endometriosis and men with very mild oligospermia, with sperm count ≥15 million per ml, were included. Women with important medical disorders were also excluded (Johnson, 2006) .
Our power calculation (Johnson, 2006) suggested a sample size of 160 women distributed between the five treatment arms in the study would be required to show an increase in the pregnancy rate from 30 to 55% by adding metformin to standard therapy (to comfortably allow for attainment of at least 122 participants required to have adequate power for this primary comparison of 'standard care' versus 'standard care plus metformin'). received CC (standard care), metformin or both for 6 months. Allocation concealment was strictly maintained by a telephone call from the recruiting research nurse to pharmacy, the research pharmacist then executing the assignment by dispensing preprepared drugs in a true third party randomization. Blinding (masking) of all parties was maintained in all cases by placebo control until the end of the course of treatment or, in the event of pregnancy, until after the pregnancy.
Study drugs
Metformin 500 mg standard release tablets, CC 50 mg tablets with identical placebo tablets (to maintain blinding) for both metformin and CC were purchased from Pacific Pharmaceuticals and packaged in our research pharmacy in Auckland. Each patient received up to two 3-month treatment packages. Drugs were commenced concurrently and standard monitoring as for a CC cycle was undertaken in each case, with any required dose modifications initiated as previously described (Johnson, 2006) . Briefly, metformin 500 mg three times daily in a gradual increasing dose over 2 weeks was given; for CC 50 mg was the initial dose and 150 mg the highest dose used. All study drugs were stopped once pregnancy was diagnosed.
Outcomes
The primary outcomes were clinical pregnancy (positive urine or serum pregnancy test plus intrauterine gestation sac on ultrasound scan or histological evidence of trophoblastic tissue with spontaneous abortion or ectopic pregnancy) that occurred within 6 months of randomization and resultant live birth. Secondary outcomes were adverse events, ovulation (confirmed if pregnancy occurred or if serum progesterone level was ≥25 nmol/l; strongly suggested if serum progesterone level was 15 -25 nmol/l), spontaneous abortion, ectopic pregnancy, multiple pregnancy and other adverse perinatal or obstetric complications. All comparisons used the Pearson x 2 test. For the combined data and for the BMI . 32 kg/m 2 subgroup, the comparison was between two proportions; for the BMI ≤ 32 kg/m 2 subgroup, the comparison was between the three treatments; for adverse events, the comparison was between the five different treatment groups. This analysis was conducted on an intention-to-treat basis using 'worst case' assumptions that women lost to follow-up did not become pregnant, or that they did not have a live birth if pregnant at the time of loss to follow-up.
Results
Study population and flow
The important baseline variables were similar among the different treatment groups in each BMI category (Table I ). Figure 1 shows the flow of participants through the trial. We assessed 677 women for eligibility, of whom 349 did not meet the criteria for inclusion (primarily couples with other causes for infertility or where there were multiple causes for infertility including PCOS) and 157 were eligible but did not wish to proceed with involvement in the study. Thus 171 women from four recruiting centres in New Zealand were randomized and included in the trial after fully informed written consent was obtained from the participants and their male partners. Women were recruited between 21 August 2003 and 28 February 2007; the last baby was delivered by a participant on 28 November 2007.
Of 33 women with BMI . 32 kg/m 2 receiving placebo, 30 completed treatment and follow-up (two of whom were not fully adherent to treatment-one experienced side effects so took a reduced dose, one misunderstood the gradual increase in dose and did this every month); three breached the protocol by stopping trial medications; 25 women who had not had confirmed ovulation 3 months into the trial received CC thereafter. Among 32 women with BMI . 32 kg/m 2 receiving metformin, 29 completed treatment and follow-up (all of whom were fully adherent to treatment)-two women were lost to follow-up, one of whom was pregnant at the time of emigration to Australia and one stopped trial medication; 22 women who had not had confirmed ovulation 3 months into the trial received CC thereafter. Among 36 women with BMI ≤ 32 kg/m 2 receiving CC, 32 completed treatment and follow-up (all of whom were fully adherent to treatment)-there was one loss to follow-up and three either stopped or failed to start treatment. Of 35 women with BMI ≤ 32 kg/m 2 receiving metformin, 32 completed treatment and follow-up (all of whom were fully adherent)-three breached the protocol by stopping treatment early, one of whom failed to resume treatment after a pregnancy miscarried. Of 35 women with BMI ≤ 32 kg/m 2 receiving CC plus metformin, 34 completed treatment and follow-up (one of whom was not fully adherent and took the trial drugs erratically)-one woman breached the protocol by failing to resume treatment after a pregnancy miscarried. Of four women who stopped taking study drugs owing to gastrointestinal side effects, only one was actually taking metformin.
Primary outcomes
Primary and secondary outcomes are expressed in Table II 
Secondary outcomes
There were no significant differences in spontaneous abortion rates (prior to 20 weeks) between women receiving different treatments; there were no late pregnancy losses (after 20 weeks) and too few ectopic pregnancies on the trial to yield useful comparisons. Four women delivered twins, all from different treatment groups and two of these women had not received CC treatment.
Although the ovulation rate appeared lower in women with BMI . 32 kg/m 2 , the ovulation rates were relatively similar in the respective treatment groups within each BMI category (Table II) . The monitoring (undertaken to minimize the risk of high order multiple pregnancy in women taking clomiphene) revealed that seven women had a serum estradiol level .2500 pmol/l, all of whom had vaginal ultrasound scans, from whom three continued without the need for further intervention, three were prescribed progestogen emergency contraception and one was advised to avoid sexual intercourse for 1 week. All seven women with high serum estradiol were receiving CC (three of whom were receiving combination CC/metformin). Ovarian ultrasound showing PCO (%) 26 (79) 25 (78) 28 (78) 31 (89) 29 (83) Biochemical androgen excess* (%) 24 (75) 22 (73) 25 (71) 23 (66) 25 (71) Hyperandrogenism † (%) 30 (91) 29 (94) 34 (94) 31 (89) 32 (91) Both PCO and hyperandrogenism (%) 24 (73) 23 (72) 26 (72) 28 (80) 24 (69) Mean total testosterone (SD) (nmol/l) (55) 23 (72) 28 (78) 22 (63) 23 (66) Nulliparous (%) 24 (73) 27 (84) 33 (92) 27 (77) 28 (80) Months related infertility. There was no evidence of differences in adverse events between treatment groups. Another finding (although based only on pilot data of small numbers) was the very similar clinical pregnancy and live birth rate among women with BMI ≤ 32 kg/m 2 treated with CC compared with those treated with metformin. The strengths of this trial are that it was a multi-centre RCT with a highly secure method of allocation concealment (third party computer randomization by a telephone call to the pharmacy) and a placebocontrolled maintenance of blinding of all parties. Although it may have been possible for participants to 'guess' what treatment they were receiving based on medication side effects, it was interesting to note that more women taking placebo stopped treatment owing to gastrointestinal side effects than those taking metformin. A further strength was the categorization according to BMI, as there is a suggestion that these ovulation induction treatments have differential effectiveness in women of different BMI-in the case of this trial the cut-off was BMI 32 kg/m 2 , the threshold below which New Zealand women qualify for government funded fertility treatment (Farquhar and Gillett, 2006; Gillett et al., 2006) rather than the World Health Organization-defined BMI 30 kg/m 2 cut-off, above which an individual is defined as obese. The main weakness was that the trial was insufficiently powered to detect what many would regard as a clinically meaningful difference-in order to detect an increase in live birth from 20 to 30% by adding metformin to standard care (80% power at 95% confidence level), 590 participants would have been required for this comparison (as opposed to the 136 participants contributing to this comparison in our trial, which exceeded the power to detect an increase in pregnancy rate from 30 to 55%, established a priori by Johnson, 2006) . Other points that may be considered weaknesses include the BMI dichotomy of BMI 32 kg/m 2 arising from a local policy thus potentially limiting generalizability, the absence of data linking outcomes to women's weight loss whereas on the trial and the fact that the metformin only treatment arm in the BMI ≤ 32 kg/m 2 subpopulation can provide only pilot data that need to be combined with data from other trials to give sufficient power for meaningful comparisons. Our results are in keeping with other RCTs that have not shown significant benefit from use of combination CC plus metformin versus CC alone (Moll et al., 2006; Legro et al., 2007; Zain et al., 2008) . It is worthy of debate whether detection smaller differences is important, as all RCTs undertaken thus far have been underpowered to detect less than a 15% difference in live birth rate, yet other second line treatments (such as gonadotrophin injections) substantially increase costs and invasiveness. We did not explore, in the lower BMI group, whether pretreatment with metformin might improve fertility outcomes-some authors have suggested that the optimal effect of metformin is achieved after 4-6 months pretreatment (Baillargeon et al., 2004; Palomba et al., 2005) . It remains true that current RCT evidence suggests that CC is a superior treatment to metformin for obese women (Legro et al., 2007; Zain et al., 2008) , although our RCT did not specifically examine this comparison in the BMI . 32 kg/m 2 group, but many authorities have questioned the appropriateness of administering ovulation induction treatment to women with obesity Lord and Norman, 2006) , the obstetric risks (both maternal and fetal) being particularly relevant in the context of gross obesity (Stotland, 2008) . However, it is unclear why the results of our New Zealand multi-centre RCT, the American multi-centre RCT data for the non-obese subpopulation of women (Table 1 of Supplementary Appendix of Legro et al., 2007, available at www.nejm .org that showed a significant advantage of CC) and the Italian RCT that showed a significant advantage of metformin (Palomba et al., 2005) were so heterogeneous in the comparison metformin versus CC for non-obese women. Whether these dramatically different results could relate to dose of metformin used, the failure to adjust metformin dose according to BMI, the preparation used (for example, a sustained release metformin was used in the American trial; Legro et al., 2007) , where the outcomes from metformin treatment were particularly poor or fundamental differences in the populations studied in terms of their response to metformin, remains unclear.
Adverse events and pregnancy complications
Our results for early pregnancy loss for women with BMI ≤ 32 kg/m 2 (four from 14 metformin pregnancies versus none from 14 CC pregnancies) are noteworthy, although based on small numbers. Legro et al. (2007) had similarly higher results for first trimester losses with metformin (40.0%) than CC (22.6%), but Palomba et al. (2005) had a lower rate of pregnancy loss in women treated with metformin (9.7%) than CC (37.5%). All these trials had a policy of stopping metformin once pregnancy was diagnosed. Whether continuation of metformin through the first trimester might lower the pregnancy loss rate among women becoming pregnant with metformin treatment is meritworthy of further investigation in robust RCTs. There is perhaps a paradox that metformin is known to give poor results for women with PCOS-related anovulatory infertility and obesity (Tang et al., 2006) , where insulin resistance tends to be more pronounced, yet we have found that the results for women with PCOS and BMI ≤ 32 kg/m 2 are as good for metformin as for CC.
Our results challenge the consensus statement that metformin should be restricted to women with known glucose intolerance (The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008; Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008) . The main disadvantage of metformin appears to be a high incidence of gastrointestinal side effects, but other studies have shown numerous potential advantages of metformin over CC. These include no known adverse endometrial effect whereas endometrial thinning could reduce embryo receptivity for some women using CC (Gonen and Casper, 1990; Wu et al., 2007) , no known increase in multiple pregnancy rate unlike that associated with CC and thus no requirement for inconvenient and costly monitoring of ovulation induction cycles that many fertility clinics insist upon for CC, no concern over long-term adverse effects on the ovaries such as the lingering concern over increased risk of ovarian cancer seen in some cohort studies of women using CC, particularly serous ovarian cancer (Jensen et al., 2009 ) and among those using long treatment courses (Rossing et al., 1994) . Nonetheless CC has had remarkable longevity as the first line treatment for anovulatory PCOS and doubtless will continue to have an important place (Homburg, 2005 Women having specific side effects: CC as first line for ovulation induction for women with ovulation dysfunction related to PCOS in the absence of obesity and this debate should not be closed.
Conclusion
There is no evidence that adding metformin to standard care is beneficial in improving pregnancy and live birth rates for women with anovulatory PCOS.
